O	0	3	Two
O	3	4	-
O	4	8	Year
O	9	15	Trends
O	16	18	of
O	19	25	Taxane
O	25	26	-
O	26	33	Induced
O	34	44	Neuropathy
O	45	47	in
O	48	53	Women
O	54	62	Enrolled
O	63	65	in
O	66	67	a
O	68	78	Randomized
O	79	84	Trial
O	85	87	of
B-intervention	88	94	Acetyl
I-intervention	94	95	-
I-intervention	95	96	L
I-intervention	96	97	-
I-intervention	97	106	Carnitine
O	107	108	(
O	108	112	SWOG
O	113	118	S0715
O	118	119	)
O	119	120	.

B-condition	121	133	Chemotherapy
I-condition	133	134	-
I-condition	134	141	induced
I-condition	142	152	peripheral
I-condition	153	163	neuropathy
I-condition	164	165	(
I-condition	165	169	CIPN
I-condition	169	170	)
O	171	173	is
O	174	175	a
O	176	182	common
O	183	186	and
O	187	196	disabling
O	197	201	side
O	202	208	effect
O	209	211	of
O	212	219	taxanes
O	219	220	.

O	221	227	Acetyl
O	227	228	-
O	228	229	L
O	229	230	-
O	230	239	carnitine
O	240	241	(
O	241	244	ALC
O	244	245	)
O	246	249	was
O	250	262	unexpectedly
O	263	268	found
O	269	271	to
O	272	280	increase
O	281	285	CIPN
O	286	288	in
O	289	290	a
O	291	301	randomized
O	302	307	trial
O	307	308	.

O	309	311	We
O	312	324	investigated
O	325	328	the
O	329	333	long
O	333	334	-
O	334	338	term
O	339	347	patterns
O	348	350	of
O	351	355	CIPN
O	356	361	among
O	362	370	patients
O	371	373	in
O	374	378	this
O	379	384	trial
O	384	385	.

O	386	391	S0715
O	392	395	was
O	396	397	a
O	398	408	randomized
O	408	409	,
O	410	416	double
O	416	417	-
O	417	422	blind
O	422	423	,
O	424	435	multicenter
O	436	441	trial
O	442	451	comparing
O	452	455	ALC
O	456	457	(
O	457	461	1000
O	462	464	mg
O	465	470	three
O	471	476	times
O	477	478	a
O	479	482	day
O	482	483	)
O	484	488	with
B-control	489	496	placebo
O	497	500	for
O	501	503	24
O	504	509	weeks
O	510	512	in
B-eligibility	513	518	women
I-eligibility	519	529	undergoing
I-eligibility	530	538	adjuvant
I-eligibility	539	545	taxane
I-eligibility	545	546	-
I-eligibility	546	551	based
I-eligibility	552	564	chemotherapy
I-eligibility	565	568	for
I-eligibility	569	575	breast
I-eligibility	576	582	cancer
O	582	583	.

O	584	588	CIPN
O	589	592	was
O	593	601	measured
O	602	604	by
O	605	608	the
O	609	611	11
O	611	612	-
O	612	616	item
O	617	630	neurotoxicity
O	631	632	(
O	632	635	NTX
O	635	636	)
O	637	646	component
O	647	649	of
O	650	653	the
O	654	658	FACT
O	658	659	-
O	659	665	Taxane
O	666	671	scale
O	672	674	at
O	675	680	weeks
O	681	683	12
O	683	684	,
O	685	687	24
O	687	688	,
O	689	691	36
O	691	692	,
O	693	695	52
O	695	696	,
O	697	700	and
O	701	704	104
O	704	705	.

O	706	708	We
O	709	717	examined
O	718	721	NTX
O	722	728	scores
O	729	733	over
O	734	737	two
O	738	743	years
O	744	749	using
O	750	756	linear
O	757	762	mixed
O	763	769	models
O	770	773	for
O	774	786	longitudinal
O	787	791	data
O	791	792	.

O	793	803	Individual
O	804	808	time
O	809	815	points
O	816	820	were
O	821	829	examined
O	830	835	using
O	836	842	linear
O	843	853	regression
O	853	854	.

O	855	865	Regression
O	866	874	analyses
O	875	883	included
O	884	898	stratification
O	899	906	factors
O	907	910	and
O	911	914	the
O	915	923	baseline
O	924	929	score
O	930	932	as
O	933	943	covariates
O	943	944	.

O	945	948	All
O	949	960	statistical
O	961	966	tests
O	967	971	were
O	972	975	two
O	975	976	-
O	976	981	sided
O	981	982	.

B-total-participants	983	987	Four
I-total-participants	987	988	-
I-total-participants	988	995	hundred
I-total-participants	996	1000	nine
O	1001	1009	subjects
O	1010	1014	were
O	1015	1023	eligible
O	1024	1027	for
O	1028	1038	evaluation
O	1038	1039	.

O	1040	1048	Patients
O	1049	1058	receiving
O	1059	1062	ALC
O	1063	1066	had
O	1067	1068	a
O	1069	1082	statistically
O	1083	1096	significantly
O	1097	1098	(
O	1098	1099	P
O	1100	1101	=
O	1102	1103	.
O	1103	1105	01
O	1105	1106	)
O	1107	1114	greater
B-outcome	1115	1124	reduction
I-outcome	1125	1127	in
I-outcome	1128	1131	NTX
I-outcome	1132	1138	scores
O	1139	1140	(
O	1140	1145	worse
O	1146	1150	CIPN
O	1150	1151	)
O	1152	1154	of
O	1155	1156	-
O	1156	1157	1
O	1157	1158	.
O	1158	1160	39
O	1161	1167	points
O	1168	1169	(
O	1169	1171	95
O	1171	1172	%
O	1173	1183	confidence
O	1184	1192	interval
O	1193	1194	[
O	1194	1196	CI
O	1196	1197	]
O	1198	1199	=
O	1200	1201	-
O	1201	1202	2
O	1202	1203	.
O	1203	1205	48
O	1206	1208	to
O	1209	1210	-
O	1210	1211	0
O	1211	1212	.
O	1212	1214	30
O	1214	1215	)
O	1216	1220	than
O	1221	1224	the
O	1225	1232	placebo
O	1233	1238	group
O	1238	1239	.

O	1240	1245	These
O	1246	1257	differences
O	1258	1262	were
O	1263	1275	particularly
O	1276	1283	evident
O	1284	1286	at
O	1287	1292	weeks
O	1293	1295	24
O	1296	1297	(
O	1297	1298	-
O	1298	1299	1
O	1299	1300	.
O	1300	1302	68
O	1302	1303	,
O	1304	1306	95
O	1306	1307	%
O	1308	1310	CI
O	1311	1312	=
O	1313	1314	-
O	1314	1315	3
O	1315	1316	.
O	1316	1318	02
O	1319	1321	to
O	1322	1323	-
O	1323	1324	0
O	1324	1325	.
O	1325	1327	33
O	1327	1328	)
O	1328	1329	,
O	1330	1332	36
O	1333	1334	(
O	1334	1335	-
O	1335	1336	1
O	1336	1337	.
O	1337	1339	37
O	1339	1340	,
O	1341	1343	95
O	1343	1344	%
O	1345	1347	CI
O	1348	1349	=
O	1350	1351	-
O	1351	1352	2
O	1352	1353	.
O	1353	1355	69
O	1356	1358	to
O	1359	1360	-
O	1360	1361	0
O	1361	1362	.
O	1362	1364	04
O	1364	1365	)
O	1365	1366	,
O	1367	1370	and
O	1371	1373	52
O	1374	1375	(
O	1375	1376	-
O	1376	1377	1
O	1377	1378	.
O	1378	1380	83
O	1380	1381	,
O	1382	1384	95
O	1384	1385	%
O	1386	1388	CI
O	1389	1390	=
O	1391	1392	-
O	1392	1393	3
O	1393	1394	.
O	1394	1396	35
O	1397	1399	to
O	1400	1401	-
O	1401	1402	0
O	1402	1403	.
O	1403	1405	32
O	1405	1406	)
O	1406	1407	.

O	1408	1410	At
O	1411	1414	104
O	1415	1420	weeks
O	1420	1421	,
B-iv-bin-percent	1422	1424	39
I-iv-bin-percent	1424	1425	.
I-iv-bin-percent	1425	1426	5
I-iv-bin-percent	1426	1427	%
O	1428	1430	on
O	1431	1434	the
O	1435	1438	ALC
O	1439	1442	arm
O	1443	1446	and
B-cv-bin-percent	1447	1449	34
I-cv-bin-percent	1449	1450	.
I-cv-bin-percent	1450	1451	4
I-cv-bin-percent	1451	1452	%
O	1453	1455	on
O	1456	1459	the
O	1460	1467	placebo
O	1468	1471	arm
O	1472	1480	reported
O	1481	1482	a
B-outcome	1483	1487	five
I-outcome	1487	1488	-
I-outcome	1488	1493	point
I-outcome	1494	1495	(
I-outcome	1495	1497	10
I-outcome	1497	1498	%
I-outcome	1498	1499	)
I-outcome	1500	1508	decrease
O	1509	1513	from
O	1514	1522	baseline
O	1522	1523	.

O	1524	1527	For
O	1528	1532	both
O	1533	1542	treatment
O	1543	1549	groups
O	1549	1550	,
B-outcome	1551	1554	104
I-outcome	1554	1555	-
I-outcome	1555	1559	week
I-outcome	1560	1563	NTX
I-outcome	1564	1570	scores
O	1571	1575	were
O	1576	1589	statistically
O	1590	1603	significantly
O	1604	1613	different
O	1614	1622	compared
O	1623	1627	with
O	1628	1636	baseline
O	1637	1638	(
O	1638	1639	P
O	1640	1641	<
O	1642	1643	.
O	1643	1646	001
O	1646	1647	)
O	1647	1648	.

O	1649	1652	For
O	1653	1657	both
O	1658	1664	groups
O	1664	1665	,
O	1666	1669	NTX
O	1670	1676	scores
O	1677	1681	were
O	1682	1689	reduced
O	1690	1694	from
O	1695	1703	baseline
O	1704	1707	and
O	1708	1716	remained
O	1717	1729	persistently
O	1730	1733	low
O	1733	1734	.

O	1735	1741	Twenty
O	1741	1742	-
O	1742	1746	four
O	1747	1752	weeks
O	1753	1755	of
O	1756	1759	ALC
O	1760	1767	therapy
O	1768	1776	resulted
O	1777	1779	in
O	1780	1793	statistically
O	1794	1807	significantly
O	1808	1813	worse
B-outcome	1814	1818	CIPN
O	1819	1823	over
O	1824	1827	two
O	1828	1833	years
O	1833	1834	.

O	1835	1848	Understanding
O	1849	1852	the
O	1853	1862	mechanism
O	1863	1865	of
O	1866	1870	this
O	1871	1881	persistent
O	1882	1888	effect
O	1889	1892	may
O	1893	1899	inform
O	1900	1910	prevention
O	1911	1914	and
O	1915	1924	treatment
O	1925	1935	strategies
O	1935	1936	.

O	1937	1942	Until
O	1943	1947	then
O	1947	1948	,
O	1949	1952	the
O	1953	1962	potential
O	1963	1971	efficacy
O	1972	1975	and
O	1976	1981	harms
O	1982	1984	of
O	1985	1993	commonly
O	1994	1998	used
O	1999	2010	supplements
O	2011	2017	should
O	2018	2020	be
O	2021	2031	rigorously
O	2032	2039	studied
O	2039	2040	.
